阿替普酶与尿激酶治疗急性心肌梗死患者的临床效果比较

Comparison of clinical effects of aleptase and urokinase in the treatment of acute myocardial infarction

目的比较阿替普酶与尿激酶治疗急性心肌梗死患者的临床效果。方法本次研究选取2012年5月到2018年5月来我院接受治疗的160例急性心肌梗死患者进行研究。将所有入组患者分为两组,观察组和对照组各80例。两组患者均接受常规治疗,观察组患者同时给予阿替普酶治疗,对照组患者同时给予尿激酶治疗。结果本次研究对两组患者临床治疗效果进行比较分析,结果发现观察组患者的总疗效率(95.3%)高于对照组的总疗效率(80.0),两组相比有差异(P<0.05)。且观察组患者的血管再梗率、心律失常发生率、心力衰竭发生率显著低于对照组,差异具统计学意义(P<0.05),观察组的血管再通率显著高于对照组,差异具统计学意义(P<0.05)。结论阿替普酶较尿激酶对急性心肌梗死患者的治疗效果好,值得临床推广。

Objective To compare the clinical effects of altipase and urokinase in the treatment of acute myocardial infarction.Methods 160 patients with acute myocardial infarction who came to our hospital for treatment from May 2012 to May 2018 were studied.All the patients in the group were divided into two groups:80 in the observation group and 80 in the control group.Both groups received routine treatment,while the observation group was treated with aleptase and the control group with urokinase.Results This study compared the clinical treatment effect of two groups of patients and found that the total treatment effi ciency(95.3 %) was higher in the observation group than in the control group(80.0),and there were differences between the two groups(P & lt;0.05).In the observation group,the rate of vascular infarction,arrhythmia,and heart failure were signifi cantly lower than those of the control group, and the difference was statistically signifi cant(P & lt;0.05) The vascular retransmission rate in the observation group was signifi cantly higher than that in the control group, and the difference was statistically significant(P & lt;0.05).Conclusion Atipase has better therapeutic effect than urokinase in patients with acute myocardial infarction and is worthy of clinical promotion.